Publications of Yvonne Genzel

Talk (126)

161.
Talk
Göbel, S.; Dallmeier, K.; Jordan, I.; de Jong, J.; Reichl, U.; Genzel, Y.: Intensified production for a yellow fever - ZIKA virus vaccine candicate. Democratization of biotherapies: new manufacturing modalities and intensification's, Oxford, UK (2023)
162.
Talk
Göbel, S.; Jaén, K. E.; Pelz, L.; Reiter , M.; Altomonte, J.; Reichl, U.; Genzel, Y.: Intensifiying OSB processes for high titer virus production. 5th large scale meeting: Orbital shaken bioreactors, Girona (Spain) (2023)
163.
Talk
Küchler, J.; Opitz, P.; Rüdiger, D.; Kupke, S. Y.; Genzel, Y.; Benndorf, D.; Reichl, U.: Absolute quantification of influenza A virus proteins during single-round replication in different host cells. 6th Workshop on Virus Dynamics, Nagoya (Japan) (2023)
164.
Talk
Pelz, L.; Dogra, T.; Boehme, J.D.; Hein, M. D.; Marichal-Gallardo, P.; Genzel, Y.; Bruder, D.; Kupke, S. Y.; Reichl, U.: Influenza A virus OP7 defective interfering particles: Cell culture-based production and antiviral efficacy in vivo. Cell Culture Engineering (CCE) XVIII , Cancun (Mexico) (2023)
165.
Talk
Pelz, L.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: In-depth characterization and cell culture-based production of influenza A virus defective interfering particles. ACTIP fellowship session, Dublin (Ireland) (2023)
166.
Talk
Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. D.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy. Vir-AI-DIP Workshop, Hamburg (Germany) (2023)
167.
Talk
Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: Novel approach towards vaccine manufacturing: from single-cell cloning to high-yielding influenza virus production. 4th Global Bioprocessing, Bioanalytics and ATMP Manufacturing Congress, Dublin (Ireland) (2023)
168.
Talk
Zinnecker, T. M.; Badri, N.; Araujo, D.; Hinkelmann, A.; Thiele, K.; Reichl, U.; Genzel, Y.: A quest for the best influenza producing clonal MDCK cell line: intensifying by design of experiments, ambr15 and bench-top bioreactor cultivations. World Biopharm Forum 2023 - Democratisation of biotherapies: new manufacturing modalities and intensifications, Oxford (United Kingdom) (2023)
169.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition):Upstream Process Development - From Master Seed to Production. ESACT Course 2022, Llafranc (Spain) (2022)
170.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition):Upstream Process Intensification. ESACT Course 2022, Llafranc (Spain) (2022)
171.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition): Overview on COVID-19 candidate vaccines. Introduction Exercise. ESACT Course 2022, Llafranc (Spain) (2022)
172.
Talk
Genzel, Y.: ESACT Course on Cell Culture-based Viral Vaccines (7th Edition): Exercise on vaccine design. ESACT Course 2022, Llafranc (Spain) (2022)
173.
Talk
Göbel, S.; Pelz, L.; Behrendt, I.; Prömmel, M.; Altomonte, J.; Anderlei, T.; Bürgin, T.; Genzel, Y.; Reichl, U.: Scale-Down of an Ortbital Shaken Bioreactor: High Cell Density Cultivation in Perfusion Mode and Virus production. Single-Use Technologies V: Building the Future, Marseille, France (2022)
174.
Talk
Gränicher, G.; Göbel, S.; Marichal-Gallardo, P.; Jordan, I.; Sandig, V.; Genzel, Y.; Reichl, U.: Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. Value through intensified bioprocessing II, Oxford, United Kingdom (2022)
175.
Talk
Gränicher, G.; Göbel, S.; Marichal-Gallardo, P.; Jordan, I.; Sandig, V.; Genzel, Y.; Reichl, U.: Integrated cell-culture based MVA virus production process with perfusion mode for vaccines or gene therapy. 27th ESACT Meeting, Lisbon (Portugal) (2022)
176.
Talk
Hein, M.; Chawla, A.; Arora , P.; Cattaneo, M.; Winkler, M.; Pöhlmann, S.; Schughart, K.; Genzel, Y.; Kupke, S. Y.; Reichl, U.: Production of influenza A virus defective interfering particles in a high cell density perfusion cultivation with continuous virus harvesting. Vaccine Technology VIII, Sitges (Spain) (2022)
177.
Talk
Hein, M.; Dogra, T.; Arora , P.; Rand , U.; Genzel, Y.; Cattaneo, M.; Winkler, M.; Cicin-Sain, L.; Bruder, D.; Schughart, K. et al.; Pöhlmann, S.; Kupke, S. Y.; Reichl, U.: Influenza A Virus-Derived Defective Interfering Particles for Antiviral Treatment. 27th ESACT Meeting, Lisbon (Portugal) (2022)
178.
Talk
Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F.G.; Genzel, Y.; Brooke, C.B.; Kupke, S. Y.; Reichl, U.: Long-Term Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing Dynamic Competition to Select Antiviral Candidates. Vaccine Technology VIII, Sitges (Spain) (2022)
179.
Talk
Pelz, L.; Rüdiger, D.; Dogra, T.; Alnaji, F. G.; Genzel, Y.; Brooke, C. B.; Kupke, S. Y.; Reichl, U.: Semi-Continuous propagation of Influenza A virus and its defective interfering particles: Analyzing the dynamic competition to select antiviral candidates. 27th ESACT Meeting, Lisbon (Portugal) (2022)
180.
Talk
Zinnecker, T. M.; Behrendt, I.; Lau , M.; Hinkelmann, A.; Thiele, K.; Badri, N.; Araujo, D.; Genzel, Y.; Reichl, U.: Automated single-cell cloning in chemically defined medium for new suspension MDCK cell lines and scale-down of influenza A virus production into ambr®15 microbioreactors. Vaccine Technology VIII, Sitges (Spain) (2022)
Go to Editor View